SIETES :: 92566 citas

Resultados de la búsqueda por ALZHEIMER REFINAR BÚSQUEDA

1.

Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]

2.

Garde D. Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment. STAT Daily Recap 2018:1. [Ref.ID 102726]

3.

Garde D. Biogen reports positive results with Alzheimer’s drug, reviving hopes for once-failed treatment. STAT Daily Recap 2018:1. [Ref.ID 102725]

4.

Anónimo. Synthetic cannabinoid may improve agitation and aggression in Alzheimer’s disease patients, research suggests. DIA Daily 2018:26 de julio. [Ref.ID 102724]

5.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]

6.

Gray SL, Walker RL, Dublin S, Yu O, Aielo Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc 2018;66:febrero. [Ref.ID 102537]

7.

Taipale H, Hamina A, Lampela P, Tanskanen A, Tiihonen J, Karttunen N, Tolpannen A-M, Hartikainen S. Is Alzheimer’s disease associated with previous opioid use?. Pain Med 2017:28 de agosto. [Ref.ID 102153]

8.

Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. The Lancet Public Health 2017;2:e149-56. [Ref.ID 101922]

9.

Obach M, Lopez P, Catalan A. Tratamiento farmacológico de la enfermedad de Alzheimer en la población de Catalu˜na. Med Clin (Barc) 2017;149:86-7. [Ref.ID 101905]

10.

Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]

11.

Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]

12.

Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]

13.

Anónimo. Solanezumab fails to reducre cognitive decline among patients with Alzheimer’s disease in clinical trial. DIA Daily 2016:1. [Ref.ID 100978]

14.

Anónimo. Alzheimer’s researchers optimistic after positive results from phase I clinical trial of aducanumab. DIA Daily 2016:3. [Ref.ID 100832]

15.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]

16.

Anónimo. Eli Lilly hopes third large-scale clinical trial will yield positive results for solanezumab as Alzheimer’s treatment. DIA Daily 2016:3. [Ref.ID 100809]

17.

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet 2016;388:505-17. [Ref.ID 100647]

18.

Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]

19.

Anónimo. Aducanumab shows encouraging results as Alzheimer’s treatment in early clinical trial. DIA Daily 2016:3. [Ref.ID 100617]

20.

Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]